One team, one vision
At the core, AMYRA consists of a complimentary team of individuals with wide-reaching strengths and competencies. Bound together by trustworthiness and a common vision, each team member is an invaluable part of realising AMYRA’s goal of positively impacting the lives of millions of people around the globe.
Team
Dr. Werner Tschollar
CEO
Werner founded AMYRA Biotech AG. He has over 25 years of experience in the pharmaceutical, biotech and financing industries. He held executive positions in BMS/Princeton, Schering Plough and Novartis, founded several biotech companies and was a co-founder of a large private equity fund in Geneva. He has an MD degree and is board certified in clinical pharmacology, holds a degree in Pharmacy and has an MBA.
Ralph Jelinski
Head Business Development
Ralph has 20+ years of experience in the banking industry, specifically in
wealth planning, distribution and private equity. He has also served 6 years as CEO/COO in a private company.
Dr. Sulay Mourabit
Head of Product Development
Sulay is a molecular biologist with over 15 years of experience in the Life Sciences. His rich scientific background has involved fundamental and translational research in climate change, ecotoxicology, Alzheimer’s, and pediatric neuro-oncology. He holds a PhD in molecular embryology and a BSc in Marine Biology.
Peter Willinger
Head of Operations
Peter has 20+ years of experience as CFO of private and publicly listed companies. During this time, he managed numerous transactions such as IPO, M&A and fundraising and directed the human resources, legal/IP, quality assurance, investor and public relations and corporate development departments. He is responsible for investor relations, strategic positioning, corporate development and overseeing M&A activities in AMYRA. He holds a degree in business administration from the University of Mannheim.
Julian Tschollar
Head of Communication and Investor Relations
Julian has over 10 years experience as an independent entrepreneur in the creative arts. During this time, he worked extensively with clients and managers, gathering sales, consultancy and communication expertise.
Over the last 3 years, Julian has worked as Head of Communication and Investor Relations for AMYRA, developing and executing strategic engagement plans designed to support key business objectives and long-term goals.
Marcel Gremaud
CFO
Marcel has 35 years of experience as an auditor, controller, consultant and CFO. He was audit manager at Ernst & Young. Now he is CFO of a publicly traded company on NASDAQ and consultant for international accounting.
Dr. Peter Stangier
Senior Advisor, Data Sciences
Peter is a results-driven entrepreneur with more than 20 years of experience in the Pharmaceutical and Biotech industry. He has broad knowledge of the Global Pharmaceutical Industry and extensive experience in Strategy & Planning, Market & Competitive Analysis, Forecasting & Financial Valuation, Business Development, and Sales Force Sizing & Effectiveness. In 2013, he founded From Data to Decisions, providing Consulting Services to early stage Life Science Companies.
Andreu Soldevila
Head CMC
Andreu is AMYRA’s Head CMC, responsible for manufacturing, product development, project management and regulatory affairs. He has 20+ years experience in the biotechnology and bio-pharmaceutical industry and is the founder of LeanBio, a company that manages, develops and manufactures biotherapeutics. He holds a PhD and BS in Biology, an MsC and BS in Biotechnology, Msc in Microbiology and Genetics and MsC in Environmental Sciences.
Board of Directors
Dr. Werner Tschollar
Chairman of the Board of Directors
Werner founded AMYRA Biotech AG. He has over 25 years of experience in the pharmaceutical, biotech and financing industries. He held executive positions in BMS/Princeton, Schering Plough and Novartis, founded several biotech companies and was a co-founder of a large private equity fund in Geneva. He has an MD degree and is board certified in clinical pharmacology, holds a degree in Pharmacy and has an MBA.
Dr. Thomas Zehnder
Member of the Board of Directors
Thomas is a co-founder of AMYRA. He has over 20 years of experience in the medtech and healthcare industries as both a senior healthcare executive and an entrepreneur. He holds a MSc from the Swiss Institute of Technology (ETH) in Zurich and a doctorate in Business Administration / Technology Management from the University of St. Gall HSG.
Douglas Gunthardt
Member of the Board of Directors
Douglas has 20 years of international leadership experience with both American high-tech and Swiss life-science corporations, including 8 years as CEO of Siegfried. He is active on boards of Ricola and XiMo, providing expertise on finance and risk management issues.
Scientific Advisory Board
Prof. Dr. Werner Weitschies
Chief Scien fic Advisor
Werner is an expert in pharmaceutical technologies, gastro-intestinal models, formulation development and testing. Since 2003, he he is a Professor of Biopharmaceutics (C4) at the Ernst-Moritz-Arndt-University of Greifswald, Germany. He has published more than 200 peer reviewed articles and 30 patents.
Prof. Dr. Dr. Gerhard Rogler
Member of Advisory Board
Gerhard is a clinical expert for celiac disease. He is scientific advisor to the Swiss Celiac Disease Society. He serves as the Chairman of the Scientific Advisory Board of the University of Zurich and Professor of Gastroenterology and Hematology and Consultant Gastroenterologist at the Zurich University Hospital, Switzerland. He has authored about 200 original peer-reviewed articles.
Prof. Dr. Knut E.A. Lundin
Member of Advisory Board
Knut is Professor of Medicine and Head of Clinical Education at the University of Oslo, Norway. He is also a consultant gastroenterologist at the endoscopy unit at Oslo University Hospital, Rikshospitalet and he is one of the leading European clinicians in the field of celiac disease. Professor Lundin currently serves as the president of the European Society for the Study of Celiac Disease.
Prof. Frits Koning
Member of Advisory Board
Frits is a Professor of Immunology at the Department of Immunohematology and Blood Transfusion at Leiden University. He also serves as Chairman of the Scientific Advisory Board of LUMC (Leiden University Medical Center). Furthermore, he served as the Director of the Celiac Disease Consortium 2004 – 2014.
Prof. Dr. Rolf Bass
Member of Advisory Board
Rolf is an expert for regulatory affairs. He set up the new Department for European and International Business of the German Federal Institute for Drugs and Medical Devices (BfArM). Today, he is a visiting Professor for Pharmaceutical Medicine, University of Basel, Switzerland where he is responsible for the postgraduate Master curricula for Regulatory Affairs within Pharmaceutical Medicine.
Dr. Gerd Bode
Member of Advisory Board
Gerd is an expert for pre-clinical and clinical drug development. From 2000 to 2005 Gerd Bode was advisor for and lecturer in toxicology at the WHO. Since 2005 he has been a lecturer at several universities and scientific advisory to numerous large and small pharma companies.
Academic Collaborators
Prof. Dr. Werner Weitschies
Chief Scien fic Advisor
Werner is an expert in pharmaceutical technologies, gastro-intestinal models, formulation development and testing. Since 2003, he he is a Professor of Biopharmaceutics (C4) at the Ernst-Moritz-Arndt-University of Greifswald, Germany. He has published more than 200 peer reviewed articles and 30 patents.
Prof. Dr. Mladen Tzvetkov
Mladen is an expert in pharmacogenetics, recombinant DNA technologies, drug transport, and drug analytics. He is a full Professor of Pharmacology and the Head of the Department of General Pharmacology at the University Medicine in Greifswald, Germany. Mladen has co-authored more than 100 peer-reviewed articles.
Prof. Dr. Stefan Engeli
Stefan is an M.D. and board-certified Clinical Pharmacologist with experience in planning and conducting clinical studies since more than 20 years. He is Professor of Clinical Pharmacology at the University Medicine Greifswald since 2021 and Head of the Greifswald Coordinating Center for Clinical Studies (KKS), a core unit of the Medical Faculty. The Institute of Pharmacology is well suited to conduct pharmacokinetic studies.
Sarah Römer
Sarah is a M.Sc. in Human Biology, with a major in Pharmacology. She has been part of the Department of General Pharmacology at the University Medicine Greifswald for 3 years and is working on drug pharmacokinetics and pharmacogenetics. Sarah has a strong background in LC-MS/MS-based drug analytics, drug transport, and genetic analyses.
